Evidence map›Paper›PMID 35008997›Full record

ArticleInternational journal of molecular sciences2022

Runx1 Messenger RNA Delivered by Polyplex Nanomicelles Alleviate Spinal Disc Hydration Loss in a Rat Disc Degeneration Model.

Cheng-Chung Chang, Hsi-Kai Tsou, Hsu-Hsin Chang, Long Yi Chan, Guan-Yu Zhuo, Tomoji Maeda, Chin-Yu Lin

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. RUNX1 promotes liver fibrosis progression through regulating TGF-β signalling.International journal of experimental pathology · 2023
    Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Molecular Imaging in Nanomedical Research 2.0.International journal of molecular sciences · 2022
    Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Cheng-Chung ChangInstitute of New Drug Development, College of Medicine, China Medical University, Taichung 40402, Taiwan.
Hsi-Kai TsouFunctional Neurosurgery Division, Neurological Institute, Taichung Veterans General Hospital, Taichung 40705, Taiwan.
Hsu-Hsin ChangInstitute of New Drug Development, College of Medicine, China Medical University, Taichung 40402, Taiwan.
Long Yi ChanInstitute of New Drug Development, College of Medicine, China Medical University, Taichung 40402, Taiwan.
Guan-Yu ZhuoInstitute of New Drug Development, College of Medicine, China Medical University, Taichung 40402, Taiwan.ORCID 0000-0002-9813-2989
Tomoji MaedaTsuzuki Institute for Traditional Medicine, College of Pharmacy, China Medical University, Taichung 40402, Taiwan.
Chin-Yu LinInstitute of New Drug Development, College of Medicine, China Medical University, Taichung 40402, Taiwan.ORCID 0000-0003-2304-7381
China Medical University · TWNational Taichung University of Science and Technology · TWNihon Pharmaceutical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vertebral disc degenerative disease (DDD) affects millions of people worldwide and is a critical factor leading to low back and neck pain and consequent disability. Currently, no strategy has addressed curing DDD from fundamental aspects, because the pathological mechanism leading to DDD is still controversial. One possible mechanism points to the homeostatic status of extracellular matrix (ECM) anabolism, and catabolism in the disc may play a vital role in the disease's progression. If the damaged disc receives an abundant amount of cartilage, anabolic factors may stimulate the residual cells in the damaged disc to secrete the ECM and mitigate the degeneration process. To examine this hypothesis, a cartilage anabolic factor, Runx1, was expressed by mRNA through a sophisticated polyamine-based PEG-polyplex nanomicelle delivery system in the damaged disc in a rat model. The mRNA medicine and polyamine carrier have favorable safety characteristics and biocompatibility for regenerative medicine. The endocytosis of mRNA-loaded polyplex nanomicelles in vitro, mRNA delivery efficacy, hydration content, disc shrinkage, and ECM in the disc in vivo were also examined. The data revealed that the mRNA-loaded polyplex nanomicelle was promptly engulfed by cellular late endosome, then spread into the cytosol homogeneously at a rate of less than 20 min post-administration of the mRNA medicine. The mRNA expression persisted for at least 6-days post-injection in vivo. Furthermore, the Runx1 mRNA delivered by polyplex nanomicelles increased hydration content by ≈43% in the punctured disc at 4-weeks post-injection (wpi) compared with naked Runx1 mRNA administration. Meanwhile, the disc space and ECM production were also significantly ameliorated in the polyplex nanomicelle group. This study demonstrated that anabolic factor administration by polyplex nanomicelle-protected mRNA medicine, such as Runx1, plays a key role in alleviating the progress of DDD, which is an imbalance scenario of disc metabolism. This platform could be further developed as a promising strategy applied to regenerative medicine.

Indexed as

Gene Transfer TechniquesMicellesNanoparticle Drug Delivery SystemAnimalsCore Binding Factor Alpha 2 SubunitDisease Models, AnimalEndocytosisGene ExpressionGenetic TherapyIntervertebral DiscIntervertebral Disc DegenerationMaleMolecular ImagingNanomedicineRatsRNA, MessengerCore Binding Factor Alpha 2 SubunitMicellesNanoparticle Drug Delivery SystemRNA, MessengerRunx1 protein, ratgene therapymolecular imagingmRNA medicinenanomaterialspolyplex nanomicelletissue engineering

Identifiers

PMID35008997
PMCPMC8745749
OpenAlexW4205140674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.